US2006140927A1PendingUtilityA1

Cytochrome P450 enzyme complexes and methods of treatment using the same

69
Individually held — no corporate assignee on recordPriority: Dec 23, 2004Filed: Dec 20, 2005Published: Jun 29, 2006
Est. expiryDec 23, 2024(expired)· nominal 20-yr term from priority
Inventors:Arthur M. Nonomura
A23L 33/12A23V 2002/00C12N 9/0077A23L 33/13A61K 31/7072A61K 35/60
69
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides methods and compositions for balancing electron reduction potentials of formulations in a manner that reduces susceptibility to changes from xenobiotics. The present invention also provides novel compositions of matter based on structuring from a mobile nucleotide integral to its architecture.

Claims

exact text as granted — not AI-modified
1 . An isolated enzyme complex comprising P450:FMN, wherein there is a plurality of FMN molecules in said complex.  
   
   
       2 . A dietary supplement composition comprising FMN together with a food product comprising a reductant or an oxidant.  
   
   
       3 . The dietary supplement composition of  claim 2 , wherein the oxidant is a flavinoid.  
   
   
       4 . A formulation comprising an oxidant that induces NADPH:cytochrome P450 reductase in animals together with a carrier.  
   
   
       5 . The formulation of  claim 4 , wherein said oxidant is selected from the group consisting of flavin mononucleotide, riboflavin, glycolate, combinations thereof, and salts and derivatives thereof.  
   
   
       6 . The formulation of  claim 4 , wherein said oxidant is FMN or a salt thereof.  
   
   
       7 . The formulation of  claim 4 , wherein said carrier is selected from the group consisting of an aqueous solution, a carbonated solution, fish oil, cod liver oil, chocolate, and a reducing sugar.  
   
   
       8 . The formulation of  claim 4 , further comprising a reductant that induces cytochrome P450 monooxygenase in said animal.  
   
   
       9 . The formulation of  claim 8 , wherein said reductant is selected from the group consisting of reducing sugars, fish oil and cod liver oil.  
   
   
       10 . The formulation of  claim 8 , wherein said reductant is xylose or glucose.  
   
   
       11 . The formulation according to  claim 8 , wherein said oxidant is FMN or a salt thereof present in an amount of from about 1 mcg to about 100 mcg and said reductant is xylose present in an amount of from about 1 gram to about 1000 grams.  
   
   
       12 . The formulation according to  claim 8 , wherein said oxidant is 1 mcg to 200 mg slow release niacin and said reductant is 1 gram to 1000 grams xylose.  
   
   
       13 . The formulation according to  claim 8 , wherein said oxidant is nicotinic acid or a salt thereof in an amount of from about 1 mcg to about 1000 mcg and said reductant is xylose in an amount of about 1 gram to about 1000 grams.  
   
   
       14 . A method of reducing the amount of xenobiotics in an animal, comprising administering to an animal an effective amount of an oxidant for inducing NADPH:cytochrome P450 reductase.  
   
   
       15 . The method according to  claim 14 , wherein said oxidant is a member selected from the group consisting of ammonium salts, flavin mononucleotide (FMN), flavins, glycolate, liver extract, menadione, nicotinic acids, nicotinamide adenine dinucleotide phosphate (NADP), riboflavin, and salts, hydrates, esters, amines, and aldehydes thereof.  
   
   
       16 . The method according to  claim 14 , wherein said oxidant is a vitamin.  
   
   
       17 . The method according to  claim 14 , wherein said oxidant is a flavin.  
   
   
       18 . The method according to  claim 14 , wherein said oxidant has an E 0  value of between about −400 mV and about −165 mV.  
   
   
       19 . The method according to  claim 14 , wherein said oxidant is selected from the group consisting of flavins, salts thereof, hydrates thereof derivatives thereof and combinations thereof.  
   
   
       20 . The method according to  claim 14 , wherein said oxidant comprises flavin mononucleotide.  
   
   
       21 . The method according to  claim 14 , wherein said oxidant comprises flavin mononucleotide and liver extracts.  
   
   
       22 . The method of  claim 14 , further comprising administering an effective amount of a reductant for inducing cytochrome P450 monooxygenase in said animal.  
   
   
       23 . The method according to  claim 14 , wherein said animal is a human.  
   
   
       24 . The method according to  claim 14 , wherein said oxidant is flavin mononucleotide in the dosage range of 0.1 mg to 10 mg.  
   
   
       25 . A topical composition comprising an effective amount of an oxidant for inducing NADPH:cytochrome P450 reductase, together with a suitable carrier.  
   
   
       26 . The topical composition of  claim 25 , further comprising an effective amount of a reductant for inducing cytochrome P450 monooxygenase.  
   
   
       27 . A carbonated beverage comprising FMN or a salt thereof.  
   
   
       28 . The beverage of  claim 27 , further comprising a reducing sugar.

Join the waitlist — get patent alerts

Track US2006140927A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.